Positive-CHMP-opinion-for-Bayers-new-symptomatic-chronic-heart-failure-treatment-vericiguat

Vericiguat is being considered for adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring intravenous therapy / Vericiguat was studied in a population with a high risk of cardiovascular death or heart failure hospitalization / European Commission decision is expected in the coming months
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news